The Filing Desk

Adaptive Biotechnologies vs Ligand Pharmaceuticals

Adaptive Biotechnologies ADPT · Ligand Pharmaceuticals LGND · Biotechnology

Adaptive Biotechnologies reported revenue of $277 million in fiscal 2025, about the same as Ligand Pharmaceuticals' $268 million in fiscal 2025. Adaptive Biotechnologies' revenue grew 54.8% in its latest year, and Ligand Pharmaceuticals' grew 60.4%. Adaptive Biotechnologies had an operating margin of -20.6%, against 15.3% at Ligand Pharmaceuticals. Free cash flow was −$49 million at Adaptive Biotechnologies and $49 million at Ligand Pharmaceuticals.

Side by side

Adaptive BiotechnologiesLigand Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$277M$268M
Revenue growth54.8%60.4%
Revenue growth a year, last 5 years23.0%10.4%
Gross margin74.2%—
Operating margin−20.6%15.3%
Net margin−21.5%46.4%
Free cash flow−$49M$49M
Free cash flow margin−17.7%18.2%
Return on capital−37.2%4.9%
Net debt to EBITDA—−3.8x
Dividends and buybacks$0M$15M
Change in diluted share count3.1%11.0%
Last close$29.04$308.79
P/E at the last close—134.3×
Insider trades, last 12 monthssold $121.6 millionsold $34.2 million
Piotroski F-score5 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Adaptive BiotechnologiesLigand Pharmaceuticals
Operating margin
Percent of revenue
Adaptive BiotechnologiesLigand Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Adaptive BiotechnologiesLigand Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Adaptive Biotechnologies and Ligand Pharmaceuticals pages.